Amphista Unveils Next-Gen 'Glue' Degraders for Tough Cancers

CAMBRIDGE, UK – March 23, 2026 – UK-based Amphista Therapeutics is set to take center stage at the upcoming American Association for Cancer Research (AACR) Annual Meeting, where it will unveil significant progress across its pipeline of next-generation cancer therapies. The company announced it will deliver three key presentations, including an invited talk on its lead clinical candidate for Acute Myeloid Leukemia (AML), highlighting the power of its proprietary "Targeted Glue™" technology in tackling some of oncology's most challenging diseases.

The presentations, scheduled for the prestigious meeting in San Diego from April 17-22, signal a pivotal moment for Amphista and the broader field of targeted protein degradation (TPD). By pioneering degraders that operate independently of the commonly used CRBN and VHL E3 ligases, the company is positioning itself at the forefront of a new wave of innovation aimed at drugging the previously undruggable.

A New Horizon for AML Treatment with AMX-883

The centerpiece of Amphista's AACR showcase will be an oral presentation on AMX-883, its clinical candidate for Acute Myeloid Leukemia. The talk, to be delivered by Chief Development Officer Martin Pass, is part of the highly anticipated "New Drugs on the Horizon" session, a platform reserved for compounds with significant clinical potential.

AMX-883 is a novel, orally bioavailable degrader of BRD9, a protein subunit critically involved in maintaining the cancerous state of AML cells. AML is a notoriously aggressive blood cancer with a grim five-year survival rate of just 33%. A key feature of the disease is a "differentiation block," where immature myeloid cells fail to mature and instead proliferate uncontrollably.

Amphista’s approach with AMX-883 is to degrade the BRD9 protein, thereby releasing this block and allowing the cancerous cells to differentiate and subsequently die. Crucially, the therapy is designed as a karyotype-independent agent, meaning its effectiveness is not tied to specific genetic mutations within a patient's cancer. This could dramatically broaden its applicability compared to more narrowly targeted therapies, addressing a major unmet need for the majority of AML patients who lack specific genetic markers for other treatments. The advancement of AMX-883 to a clinical candidate stage offers a tangible new strategy for a disease that claims an estimated 130,000 lives globally each year.

Expanding the TPD Toolbox Beyond Convention

Beyond its lead program, Amphista will present compelling preclinical data from two other programs that underscore the versatility of its Eclipsys® discovery platform. These poster presentations reveal how the company is systematically expanding the targeted protein degradation toolbox by recruiting novel E3 ligases—the cellular machinery responsible for tagging proteins for destruction.

One poster details the development of selective SMARCA2 degraders for the treatment of SMARCA4-deficient non-small cell lung cancer (NSCLC). These mutations, found in over 5% of NSCLC patients, are linked to poor prognosis. Amphista's strategy exploits a concept known as paralogue dependency, selectively destroying the SMARCA2 protein in cancer cells that lack its partner, SMARCA4, leading to cell death with minimal impact on healthy tissue. The data demonstrates that these "Targeted Glues" potently trigger over 95% degradation of SMARCA2 within hours by uniquely hijacking the DCAF16 E3 ligase, a mechanism distinct from the conventional CRBN/VHL pathways.

A second poster will introduce a novel class of TEAD degraders for mesothelioma and NSCLC, cancers where the Hippo signaling pathway is often dysregulated. Here, Amphista showcases a clever chemical biology approach, using an "aldehyde-mediated degron" to engage the FBXO22 E3 ligase. This work not only provides a promising therapeutic candidate but also establishes new design principles for an entire class of degraders, demonstrating a rational, systematic approach to drug discovery.

Navigating a Competitive and Accelerating Field

Amphista's announcements arrive at a time of intense activity and optimism in the TPD space. The AACR 2026 meeting is expected to be a hotbed of TPD research, with numerous companies like Nurix Therapeutics and Arvinas presenting their own advancements. The entire field is eagerly awaiting a watershed moment: the anticipated FDA approval of the first PROTAC degrader, which would provide ultimate validation for the therapeutic modality and likely unlock a new surge of investment.

In this dynamic environment, differentiation is key. While many first-generation degraders, primarily PROTACs, rely on the E3 ligases CRBN and VHL, analysts note an "explosive growth in novel degradation strategies." This is precisely where Amphista is carving its niche. By successfully developing degraders that recruit alternative E3 ligases like DCAF16 and FBXO22, the company is not only expanding the universe of potential cancer targets but also creating potential solutions for cancers that might develop resistance to CRBN/VHL-based therapies.

"The ability to move beyond CRBN and VHL is a critical next step for the field," commented one industry analyst not affiliated with the company. "It opens up new biology and provides more tools to tackle disease. Companies that can demonstrate a robust, repeatable platform for doing this, as Amphista appears to be doing, are the ones to watch."

The 'Targeted Glue' Advantage

At the heart of Amphista's strategy is its Eclipsys® platform, which generates what the company calls "Targeted Glues." Unlike larger PROTAC molecules, which act as a bridge with two distinct heads, molecular glues are typically smaller molecules that induce a new binding surface between the target protein and an E3 ligase. This can often translate into more favorable drug-like properties, such as better oral bioavailability and cell permeability.

Historically, the discovery of molecular glues has been largely serendipitous. Amphista's platform aims to make this process rational and predictable. The detailed structural and mechanistic studies presented in its AACR abstracts, including the use of cryo-EM to visualize the protein complexes, demonstrate a sophisticated, structure-guided approach to optimizing potency, kinetics, and selectivity.

This scientific rigor has attracted a blue-chip syndicate of investors, including Novartis Venture Fund, Eli Lilly, and Forbion, signaling strong confidence from pharmaceutical giants and seasoned biotech funders. The upcoming presentations will provide the first public look at the fruits of this platform, moving beyond theoretical promise to concrete data on multiple high-value oncology targets. For patients with aggressive cancers like AML and NSCLC, this progress represents a meaningful step toward a new generation of more precise and effective medicines.